ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial

Biological Psychiatry

Volumn 79, Issue 12, 2016, Pages 952-961

  Lieberman, Jeffrey A ^a   Davis, Robert E ^b,c   Correll, Christoph U ^d,e   Goff, Donald C ^f,g   Kane, John M ^d,e   Tamminga, Carol A ^h   Mates, Sharon ^b   Vanover, Kimberly E ^b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Intra Cellular Therapies Inc   (United States)

^c 3 D Pharmaceutical Consultants ^*  (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Comorbid depression; Negative symptoms; Positive symptoms; Prosocial factor; Safety

Indexed keywords

CHOLESTEROL; GLUCOSE; LUMATEPERONE; PLACEBO; PROLACTIN; RISPERIDONE; TRIACYLGLYCEROL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROLEPTIC AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIET RESTRICTION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECT SIZE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; OUTCOME ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84945899431     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.08.026     Document Type: Article

References (26)

1. 1 Kane, J.M., Correll, C.U., Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71 (2010), 1115–1124.
2. 2 Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2163–2196.
3. 3 Millan, M.J., Fone, K., Steckler, T., Horan, W.P., Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 24 (2014), 645–692.
4. 4 De Hert, M., Detraux, J., van Winkel, R., Yu, W., Correll, C.U., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8 (2012), 114–126.
5. 5 Nielsen, J., Correll, C.U., Manu, P., Kane, J.M., Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided?. J Clin Psychiatry 74 (2013), 603–613.
6. 6 Li, P., Zhang, Q., Robichaud, A.J., Lee, T., Tomesch, J., Yao, W., et al. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem 57 (2014), 2670–2682.
7. 7 Snyder, G.L., Vanover, K.E., Zhu, H., Miller, D.B., O'Callaghan, J.P., Tomesch, J., et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 232 (2015), 605–621.
8. 8 Meltzer, H.Y., Matsubara, S., Lee, J.C., Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251 (1989), 238–246.
9. 9 Goebel-Goody, S.M., Davies, K.D., Alvestad Linger, RM, Freund, RK, Browning, MD, Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience 158 (2009), 1446–1459.
10. 10 Laruelle, M., Frankle, W.G., Narendran, R., Kegeles, L.S., Abi-Dargham, A., Mechanism of action of antipsychotic drugs: From dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 27:suppl A (2005), S16–S24.
11. 11 Javitt, D.C., Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78 (2007), 69–108.
12. 12 Schwartz, T.L., Sachdeva, S., Stahl, S.M., Glutamate neurocircuitry: Theoretical underpinnings in schizophrenia. Front Pharmacol, 3, 2012, 195.
13. 13 Meyer, J.H., Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32 (2007), 86–102.
14. 14 Davis, R.E., Vanover, K.E., Zhou, Y., Brasic, J.R., Guevara, M., Bisuna, B., et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT and dopamine D receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl) 232 (2015), 2863–2872.
15. 15 Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005), 1209–1223.
16. 16 First, M.B., Williams, J.B.W., Spitzer, R.L., Gibbon, M., Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). 2007, Biometrics Research, New York State Psychiatric Institute, New York.
17. 17 Targum, S.D., Pendergrass, J.C., Toner, C., Asgharnejad, M., Burch, D.J., Audio-digital recordings used for independent confirmation of site-based MADRS interview scores. Eur Neuropsychopharmacol 24 (2014), 1760–1766.
18. 18 Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987), 261–276.
19. 19 Sharp, I.R., Kobak, K.A., Osman, D.A., The use of videoconferencing with patients with psychosis: A review of the literature. Ann Gen Psychiatry, 10, 2011, 14.
20. 20 Purnine, D.M., Carey, K.B., Maisto, S.A., Carey, M.P., Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders. J Nerv Ment Dis 188 (2000), 653–661.
21. 21 Turner, E.H., Knoepflmacher, D., Shapley, L., Publication bias in antipsychotic trials: An analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med, 9, 2012, e1001189.
22. 22 Ballon, J.S., Pajvani, U., Freyberg, Z., Leibel, R.L., Lieberman, J.A., Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 25 (2014), 593–600.
23. 23 Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey, D.E., Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 (2005), 1115–1121.
24. 24 Peuskens, J., Pani, L., Detraux, J., De Hert, M., The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs 28 (2014), 421–453.
25. 25 Vancampfort, D., Wampers, M., Mitchell, A.J., Correll, C.U., De Herdt, A., Probst, M., De Hert, M., A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 12 (2013), 240–250.
26. 26 Miyamoto, S., Miyake, N., Jarskog, L.F., Fleischhacker, W.W., Lieberman, J.A., Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17 (2012), 1206–1227.